From Shanghai Jiao Tong University Lab toward IND: Medicilon Accelerates PentoGen’s Oligonucleotide Pipeline
November 5, marking Medicilon’s 7th IPO anniversary, Medicilon entered a strategic collaboration agreement with PentoGen. The two parties will jointly conduct preclinical pharmacokinetic and safety assessments for PentoGen’s oligonucleotide pipeline targeting metabolic disorders. Medicilon will deliver one-stop services covering preclinical studies and IND-enabling support to advance academic-originated innovations toward clinical development. November 5, marking Medicilon’s […]
Giving Back to the Alma Mater, Carrying the Torch Forward: Medicilon Donates RMB 10 Million to China Pharmaceutical University
Seven years since its IPO, Medicilon gives back to its alma mater; marking nine decades of excellence, China Pharmaceutical University(CPU) fosters innovation through talent development. November 5, 2025 — On the occasion of Medicilon’s seventh anniversary as a listed company and the 90th anniversary of CPU, Medicilon donated RMB 10 million to the China Pharmaceutical […]
JSSX 2026

Nov. 16(Mon.) – 19 (Thu.), 2026. Venue: Tsukuba International Congress Center, Tsukuba, Japan.
7th Anniversary Q&A 3: Seven Years Since STAR Market Listing, How Has Medicilon Mastered Emerging Technologies amid Rapid AI and New Modalities Advances?
AI, XDCs, small nucleic acids, macrocyclic peptide, in vivo CAR‑T and radiopharmaceuticals are reshaping the global landscape of novel drug R&D. Seven years after its STAR Market listing, Medicilon keeps pace with this paradigm shift. We proactively build service platforms ahead of market needs and industry changes, developing a diversified preclinical service ecosystem spanning from […]
7th Anniversary Q&A 2: With nearly 700 INDs enabled by Medicilon, what transformations have reshaped China’s innovative drug sector?
Over the seven years since its STAR Market listing, Medicilon has supported nearly 700 candidates to secure IND approvals for clinical trials. Beyond this figure, a more profound shift is unfolding: China’s innovative drug industry is undergoing remarkable transformation. R&D has advanced from feasibility validation to clinical-stage development, and from China-only filings to global advancement […]
7th Anniversary Q&A 1: Seven Years Since STAR Market Listing, How Has Medicilon Weathered Industry Cycles to Deliver Resilient Growth?
Seven years on, the biopharma industry has completed a full market cycle. Amid the tides of change, some players ride the swings, while others build strength for sustained growth. Since its STAR Market listing seven years ago, Medicilon has delivered resilient growth: steady expansion from 2019 to 2022; cyclical adjustments amid industry headwinds in 2023–2024; […]
Medicilon presented the ” Excellence in Client Partnership Award ” to it long-time collaboration partner Revolution Medicines
Shanghai, October 15, 2026 — Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited the Medicilon Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon’s Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President, and their team extended a warm reception. The two parties […]
Breaking the “King of Cancer”: First-in-Class ADC MC001. Medicilon Supports Partner Medicovestor to Secure FDA IND Clearance
Recently, Medicovestor, Inc. has obtained IND clearance from the FDA for MC001, a novel ADC candidate developed for pancreatic cancer treatment. Medicilon’s support As Medicovestor’s preclinical CRO partner, Medicilon performed non-GLP and GLP toxicology studies for MC001. With professional and efficient R&D services, Medicilon supported this first-in-class ADC to successfully secure FDA IND approval. The […]
Medicilon’s Dr. Chunlin Chen Engages FDA Experts at SAPA-DC Annual Conference to Discuss Global IND Development and NAMs Technologies for Innovative Medicines
October 18, 2026 — The 2026 SAPA-DC Annual Conference concluded successfully at the Gaithersburg Marriott in Maryland. Centered on the theme “From Innovation to Global Product: Building FDA‑Ready Biopharmaceutical Companies”, the event welcomed Dr. Chunlin Chen, Founder, Chairman and CEO of Medicilon. He delivered a keynote address and participated in a panel discussion alongside distinguished […]
Medicilon TPD (PROTAC, Molecular Glue) Service Platform
Targeted protein degradation (TPD) is a promising therapeutic strategy that harnesses the intracellular proteasome or lysosome system to eliminate disease-causing proteins. TPD offers several advantages over traditional therapies, including the ability to target previously “undruggable” proteins, overcome drug resistance, and achieve high selectivity. Key TPD modalities like PROTACs and molecular glues have seen advancements in […]